Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023

Published on : Published by : Sarah Ellinwood

Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023 By Sarah EllinwoodMay 26, 2023 Funding, Awards and Collaborations Adaptive Phage Therapeutics Partners with Hebrew University, Hadassah Medical [….]

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Published on : Published by : BioBuzz Media

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the first patient has been dosed in Cohort 2 of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).